VEGFA and diabetic retinopathy: Considering the effective inhibitory effect of r-C2 on CNV formation and vascular leakage in vivo, an anti-human VEGF repebody can be further developed as a therapeutic agent for various VEGF-mediated ocular neovascular diseases such as wet AMD, diabetic retinopathy, and other retinal disorders.